Today, the FDA approved an immunotherapy for endometrial cancers that have a specific genetic feature known as dMMR which contain abnormalities that affect the proper repair of DNA inside the cell.
Read more: FDA Approves Immunotherapy for Endometrial Cancer with Specific Biomarker